Vical Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
53,497.00
47,152.00
39,954.00
38,932.00
60,691.00
48,071
Total Accounts Receivable
4,590.00
-
-
-
-
-
Other Current Assets
-
4,178.00
4,544.00
3,422.00
5,124.00
1,128
Total Current Assets
58,087.00
51,330.00
44,498.00
42,354.00
65,815.00
49,199
Net Property, Plant & Equipment
3,935.00
2,639.00
1,873.00
1,173.00
606.00
100
Total Investments and Advances
1,980.00
1,971.00
2,052.00
2,046.00
2,209.00
2,386
Intangible Assets
1,972.00
1,660.00
1,300.00
810.00
703.00
-
Other Assets
379.00
379.00
191.00
5,901.00
11,161.00
659
Total Assets
66,353.00
57,979.00
49,914.00
52,284.00
80,494.00
52,344
Accounts Payable
395.00
227.00
733.00
326.00
1,213.00
Other Current Liabilities
3,258.00
4,974.00
3,429.00
6,819.00
15,704.00
Total Current Liabilities
3,653.00
5,201.00
4,162.00
7,145.00
16,917.00
Other Liabilities
1,288.00
856.00
359.00
-
-
Total Liabilities
4,941.00
6,057.00
4,521.00
7,145.00
16,917.00
Common Equity (Total)
61,412.00
51,922.00
45,393.00
45,139.00
63,577.00
Total Shareholders' Equity
61,412.00
51,922.00
45,393.00
45,139.00
63,577.00
Total Equity
61,412.00
51,922.00
45,393.00
45,139.00
63,577.00
Liabilities & Shareholders' Equity
66,353.00
57,979.00
49,914.00
52,284.00
80,494.00

About Vical

View Profile
Address
10390 Pacific Center Court
San Diego California 92121
United States
Employees -
Website http://www.vical.com
Updated 07/08/2019
Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. It has active development programs which comprises of ongoing phase 2 trial of HSV-2 therapeutic vaccine, VCL-HB01, to treat patients with symptomatic genital herpes infection; ongoing phase 2 trial of novel antifungal VL-2397, for the treatment of patients with invasive aspergillosis; and early stage development program of a novel treatment for chronic hepatitis B virus (CHB) infection based on its DNA and lipid-delivery technologies. The company was founded by Howard E.